Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 170

Similar articles for PubMed (Select 24374933)

1.

Effects of TP53 mutational status on gene expression patterns across 10 human cancer types.

Parikh N, Hilsenbeck S, Creighton CJ, Dayaram T, Shuck R, Shinbrot E, Xi L, Gibbs RA, Wheeler DA, Donehower LA.

J Pathol. 2014 Apr;232(5):522-33. doi: 10.1002/path.4321. Epub 2014 Jan 29.

2.

Gene expression profiles modulated by the human carcinogen aristolochic acid I in human cancer cells and their dependence on TP53.

Simões ML, Hockley SL, Schwerdtle T, da Costa GG, Schmeiser HH, Phillips DH, Arlt VM.

Toxicol Appl Pharmacol. 2008 Oct 1;232(1):86-98. doi: 10.1016/j.taap.2008.06.006. Epub 2008 Jun 25.

PMID:
18639569
3.

Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status.

Bouchalova P, Nenutil R, Muller P, Hrstka R, Appleyard MV, Murray K, Jordan LB, Purdie CA, Quinlan P, Thompson AM, Vojtesek B, Coates PJ.

J Pathol. 2014 Jul;233(3):238-46. doi: 10.1002/path.4356. Epub 2014 May 21.

PMID:
24687952
4.

CKIα ablation highlights a critical role for p53 in invasiveness control.

Elyada E, Pribluda A, Goldstein RE, Morgenstern Y, Brachya G, Cojocaru G, Snir-Alkalay I, Burstain I, Haffner-Krausz R, Jung S, Wiener Z, Alitalo K, Oren M, Pikarsky E, Ben-Neriah Y.

Nature. 2011 Feb 17;470(7334):409-13. doi: 10.1038/nature09673.

PMID:
21331045
5.

Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry.

Nenutil R, Smardova J, Pavlova S, Hanzelkova Z, Muller P, Fabian P, Hrstka R, Janotova P, Radina M, Lane DP, Coates PJ, Vojtesek B.

J Pathol. 2005 Nov;207(3):251-9.

PMID:
16161005
6.
7.

Potential tumorigenic programs associated with TP53 mutation status reveal role of VEGF pathway.

Joshi H, Bhanot G, Børresen-Dale AL, Kristensen V.

Br J Cancer. 2012 Nov 6;107(10):1722-8. doi: 10.1038/bjc.2012.461. Epub 2012 Oct 18.

8.

Allelic expression imbalance of TP53 mutated and polymorphic alleles in head and neck tumors.

Ganci F, Conti S, Fontemaggi G, Manciocco V, Donzelli S, Covello R, Muti P, Strano S, Blandino G, Spriano G.

OMICS. 2011 Jun;15(6):375-81. doi: 10.1089/omi.2010.0142. Epub 2011 Feb 24.

PMID:
21348641
9.

Fbxw7/Cdc4 is a p53-dependent, haploinsufficient tumour suppressor gene.

Mao JH, Perez-Losada J, Wu D, Delrosario R, Tsunematsu R, Nakayama KI, Brown K, Bryson S, Balmain A.

Nature. 2004 Dec 9;432(7018):775-9.

PMID:
15592418
10.

Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis.

Yemelyanova A, Vang R, Kshirsagar M, Lu D, Marks MA, Shih IeM, Kurman RJ.

Mod Pathol. 2011 Sep;24(9):1248-53. doi: 10.1038/modpathol.2011.85. Epub 2011 May 6.

11.

TP53 genomic status regulates sensitivity of gastric cancer cells to the histone methylation inhibitor 3-deazaneplanocin A (DZNep).

Cheng LL, Itahana Y, Lei ZD, Chia NY, Wu Y, Yu Y, Zhang SL, Thike AA, Pandey A, Rozen S, Voorhoeve PM, Yu Q, Tan PH, Bay BH, Itahana K, Tan P.

Clin Cancer Res. 2012 Aug 1;18(15):4201-12. doi: 10.1158/1078-0432.CCR-12-0036. Epub 2012 Jun 6.

12.

p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM.

Song H, Hollstein M, Xu Y.

Nat Cell Biol. 2007 May;9(5):573-80. Epub 2007 Apr 8.

PMID:
17417627
13.

Clinical significance of PICT1 in patients of hepatocellular carcinoma with wild-type TP53.

Ishibashi M, Kogo R, Shibata K, Ueo H, Uchi R, Matsumura T, Takano Y, Sawada G, Takahashi Y, Mima K, Kurashige J, Akiyoshi S, Iwaya T, Eguchi H, Sudo T, Sugimachi K, Suzuki A, Wakabayashi G, Mori M, Mimori K.

Ann Surg Oncol. 2013 Dec;20 Suppl 3:S537-44. doi: 10.1245/s10434-013-2958-x. Epub 2013 Mar 27.

PMID:
23532381
14.

High incidence of loss of heterozygosity at chromosome 17p13 in breast tumours from BRCA2 mutation carriers.

Eiriksdottir G, Barkardottir RB, Agnarsson BA, Johannesdottir G, Olafsdottir K, Egilsson V, Ingvarsson S.

Oncogene. 1998 Jan 8;16(1):21-6.

15.

Functional characterisation of p53 mutants identified in breast cancers with suboptimal responses to anthracyclines or mitomycin.

Berge EO, Huun J, Lillehaug JR, Lønning PE, Knappskog S.

Biochim Biophys Acta. 2013 Mar;1830(3):2790-7.

PMID:
23246812
16.

Expression of genes related to apoptosis, cell cycle and signaling pathways are independent of TP53 status in urinary bladder cancer cells.

da Silva GN, Evangelista AF, Magalhães DA, Macedo C, Búfalo MC, Sakamoto-Hojo ET, Passos GA, Salvadori DM.

Mol Biol Rep. 2011 Aug;38(6):4159-70. doi: 10.1007/s11033-010-0536-x. Epub 2010 Nov 30.

PMID:
21116856
17.

P53 in human melanoma fails to regulate target genes associated with apoptosis and the cell cycle and may contribute to proliferation.

Avery-Kiejda KA, Bowden NA, Croft AJ, Scurr LL, Kairupan CF, Ashton KA, Talseth-Palmer BA, Rizos H, Zhang XD, Scott RJ, Hersey P.

BMC Cancer. 2011 May 27;11:203. doi: 10.1186/1471-2407-11-203.

18.

Gene expression profiling of isogenic cells with different TP53 gene dosage reveals numerous genes that are affected by TP53 dosage and identifies CSPG2 as a direct target of p53.

Yoon H, Liyanarachchi S, Wright FA, Davuluri R, Lockman JC, de la Chapelle A, Pellegata NS.

Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15632-7. Epub 2002 Nov 15.

19.

Distinctive patterns of p53 protein expression and microsatellite instability in human colorectal cancer.

Nyiraneza C, Jouret-Mourin A, Kartheuser A, Camby P, Plomteux O, Detry R, Dahan K, Sempoux C.

Hum Pathol. 2011 Dec;42(12):1897-910. doi: 10.1016/j.humpath.2010.06.021. Epub 2011 Jun 12.

PMID:
21665242
20.

High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.

Holstege H, Joosse SA, van Oostrom CT, Nederlof PM, de Vries A, Jonkers J.

Cancer Res. 2009 Apr 15;69(8):3625-33. doi: 10.1158/0008-5472.CAN-08-3426. Epub 2009 Mar 31.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk